Osteonecrosis of the Jaws in Patient Received Bisphosphonates and Sunitinib Separately: A Case Report

about

Osteonecrosis of the Jaws in Patient Received Bisphosphonates and Sunitinib Separately: A Case Report

Item

http://www.wikidata.org/entity/Q42269851

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Osteonecrosis of the Jaws in P ...... inib Separately: A Case Report

@en

Osteonecrosis of the Jaws in P ...... inib Separately: A Case Report

@nl

type

Item

label

Osteonecrosis of the Jaws in P ...... inib Separately: A Case Report

@en

Osteonecrosis of the Jaws in P ...... inib Separately: A Case Report

@nl

prefLabel

Osteonecrosis of the Jaws in P ...... inib Separately: A Case Report

@en

Osteonecrosis of the Jaws in P ...... inib Separately: A Case Report

@nl

P1476

Osteonecrosis of the Jaws in P ...... inib Separately: A Case Report

@en

P2093

Ali Derakhshandeh

http://www.w3.org/2001/XMLSchema#string

Azadeh Moghaddas

http://www.w3.org/2001/XMLSchema#string

Bijan Movahedian

http://www.w3.org/2001/XMLSchema#string

Farzaneh Ashrafi

http://www.w3.org/2001/XMLSchema#string

P2860

A method for estimating the probability of adverse drug reactions

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.

Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.

Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.

Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.

P304

182-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.4103/JRPP.JRPP_17_36

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29026845

http://www.w3.org/2001/XMLSchema#string

P932

5632940

http://www.w3.org/2001/XMLSchema#string